Randomized, Open-label and Multi-center Clinical Trial to Evaluate the Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' With Nexavar in Advanced Hepatocellular Carcinoma Patients

Trial Profile

Randomized, Open-label and Multi-center Clinical Trial to Evaluate the Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' With Nexavar in Advanced Hepatocellular Carcinoma Patients

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2016

At a glance

  • Drugs T-lymphocyte cell therapy (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Green Cross Cell
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 04 Mar 2016 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top